PKPD assessment of the anti-CD20 antibody obinutuzumab in cynomolgus monkey is feasible despite marked anti-drug antibody response in this species.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of pharmaceutical sciences"
DOI: 10.1016/j.xphs.2019.07.013
Abstract: The pharmacokinetics (PK) of the anti-CD20 monoclonal antibody obinutuzumab was assessed following single intravenous dosing to cynomolgus monkeys. In addition, the pharmacokinetic-pharmacodynamic (PKPD) relationship for B-cell depletion was characterized. The PKPD model was used to… read more here.
Keywords: response; antibody; antibody obinutuzumab; clearance ... See more keywords